Zydus Wellness Limited has informed the Exchange about Transcript
ZYDUSWELL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Wellness reported Q1 FY26 consolidated net sales of Rs. 8,577 million, up 2.2% YoY, with the headline number weighed down by an early and extended monsoon that hit seasonal brands Nycil and Glucon D. Excluding seasonal brands, the company posted a strong double-digit growth, helped by the recently acquired Rite Bite Max Protein (Naturell) business. Personal care segment grew 3.8% and food & nutrition grew 1.6% YoY. EBITDA was nearly flat at Rs. 1,556 million (up 0.2%), while PAT fell 13.4% on non-cash items including amortization of acquired intangibles and deferred tax. Gross margins dipped 73 bps in the quarter due to a product mix shift, though management emphasised that 361 bps of cumulative expansion has been delivered over FY24-FY25. The company is back to a net cash positive position and is investing in distribution, automation, and infrastructure. Channel mix improved with organized trade saliency rising to 30.9% (from 23.3%) and e-commerce at 14.5%.
Investors should note that the weak headline growth is largely a weather-driven, one-quarter seasonal issue and is already largely absorbed in Q1. Management's reiteration of a 2-3 year structural double-digit growth path, margin recovery from product mix and operating leverage, and the outperformance of the Rite Bite acquisition are positives. The 13.4% PAT decline and gross margin dip in Q1 may keep the stock range-bound in the near term, but the medium-term thesis around growth recovery and margin expansion remains intact.